Paul Lytle has served as Actuate Therapeutics' Chief Financial Officer since June 1, 2024, after serving as Interim Chief Financial Officer from February 2024. He brings over 30 years of finance and accounting experience and more than 25 years serving Nasdaq-listed biotechnology companies. He served as Chief Financial Officer of Avid Bioservices, Inc. (formerly Peregrine Pharmaceuticals) for more than 18 years between 1997 and 2018, where he raised over $500 million across equity and debt offerings and helped build a biologics contract-manufacturing business. He is a co-founder and CFO of Thendor Therapeutics, LLC (since September 2023) and a co-founder, director and former EVP/CFO of Mosaic ImmunoEngineering, Inc., and earlier served as EVP and CFO of Breathe Technologies, Inc. (acquired by Hillrom Holdings in 2019). Mr. Lytle received a B.S. in Business with an emphasis in Accounting from California State University, Long Beach, and is a Certified Public Accountant (inactive).